Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
Vuylsteke, P
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 11 2016 - 2059-2066 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1569-8041
10.1093/annonc/mdw320 doi
Adult
Aged
Antibodies, Monoclonal, Humanized--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Breast Neoplasms--drug therapy
Class I Phosphatidylinositol 3-Kinases--antagonists & inhibitors
Disease-Free Survival
Female
Humans
Indazoles--administration & dosage
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local--drug therapy
Paclitaxel--administration & dosage
Receptor, ErbB-2--genetics
Sulfonamides--administration & dosage
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 11 2016 - 2059-2066 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1569-8041
10.1093/annonc/mdw320 doi
Adult
Aged
Antibodies, Monoclonal, Humanized--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Breast Neoplasms--drug therapy
Class I Phosphatidylinositol 3-Kinases--antagonists & inhibitors
Disease-Free Survival
Female
Humans
Indazoles--administration & dosage
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local--drug therapy
Paclitaxel--administration & dosage
Receptor, ErbB-2--genetics
Sulfonamides--administration & dosage